Market Overview

Protalix Says Reviewing Partnering, Other Alternatives

Related PLX
Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented at the 38th European Cystic Fibrosis Conference
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

Protalix BioTherapeutics, Inc. (NYSE: PLX) confirms, in response to inquiries received this morning and a report appearing in the Israeli press, that the company has engaged Citigroup to assist it in reviewing a broad array of product partnering, technology sharing and other strategic alternatives. There is no assurance that Protalix will undertake any such strategic alternative.

Protalix will not comment further on this initiative unless future events would make doing so appropriate.

Posted-In: News


Related Articles (PLX)

Around the Web, We're Loving...

Get Benzinga's Newsletters